Phase 2/3 Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
Status:
Not yet recruiting
Trial end date:
2028-03-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in
pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).